Xphozah® (tenapanor) – New drug approval
October 17, 2023 - Ardelyx announced the FDA approval of Xphozah (tenapanor), to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Top